{"id":9171,"date":"2026-02-08T11:08:40","date_gmt":"2026-02-08T16:08:40","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=9171"},"modified":"2026-07-16T10:55:43","modified_gmt":"2026-07-16T14:55:43","slug":"menopause-endokrine-kardiovaskulare-risiken","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/de\/menopause-endocrine-cardiovascular-risks\/","title":{"rendered":"Kardiovaskul\u00e4re endokrine Risiken in den Wechseljahren"},"content":{"rendered":"

Neurobiological, Bioenergetic, and Sociosystemic Analysis of the Menopausal Transition<\/h2>\n

The Cardiovascular- Neuroendocrine Metamorphosis and the Bioenergetic Crisis of the Aging Female<\/h3>\n

The menopausal transition is not simply a local shutdown of reproductive function; it is a far-reaching neuroendocrine reconfiguration marked by declining levels and unpredictable oscillations of ovarian steroids. [1] For the female brain, this shift functions like a metabolic \u201creset.\u201d Estrogen\u2014especially 17\u03b2-estradiol (E2)\u2014acts as a central coordinator of cerebral bioenergetics, helping meet the brain\u2019s constant energy requirements for synaptic activity and cognitive robustness. [2] In hippocampal and cortical neurons, estrogen-driven signaling is tightly coupled to the preservation of aerobic glycolysis and oxidative phosphorylation. [2] By supporting ATP production through citric-acid-cycle flux and by promoting glucose availability (including upregulation of transporters such as GLUT1), E2 helps keep glucose as the dominant fuel used by the central nervous system. [2]<\/p>\n

As women near 57 years of age\u2014often several years after menopause\u2014glucose utilization in the brain can be measurably diminished after prolonged loss of estrogen\u2019s regulatory effects. [3] The result is a sustained bioenergetic strain. Evidence supports an early, possibly contributory role for mitochondrial dysfunction and brain hypometabolism in the cascade that leads to Alzheimer\u2019s disease (AD) pathology. [3, 4, 5] When glucose metabolism becomes insufficient, the brain compensates by shifting toward alternative energy pathways: first relying more heavily on ketone-based metabolism and, with progression, moving further into fatty acid oxidation (FAO). [4, 5] This adaptation carries risk; FAO has been linked to white matter injury and increased ketone-body burden. [4, 5] In effect, the brain may begin to consume endogenous lipid stores\u2014particularly myelin in white matter\u2014to maintain energy supply, promoting deterioration of connectivity and circuit integrity. [4, 5]<\/p>\n

\"\"<\/p>\n

Table 1. Comparative Bioenergetic Parameters Across the Menopausal Transition<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Bioenergetic Parameter<\/strong><\/td>\nEstrogen-Rich State (Premenopause)<\/strong><\/td>\nEstrogen-Depleted State (Postmenopause)<\/strong><\/td>\nImplications for Neurodegeneration<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Primary fuel source<\/strong><\/td>\nGlucose (aerobic glycolysis) [2]<\/td>\nKetone bodies \/ fatty acids [4, 5]<\/td>\nHigher amyloid vulnerability; white matter loss [4, 5]<\/td>\n<\/tr>\n
ATP generation efficiency<\/strong><\/td>\nOptimized via TCA\/OXPHOS [2]<\/td>\nReduced; mitochondrial hypofunction [4, 5]<\/td>\nLower neuronal stress tolerance [4, 5]<\/td>\n<\/tr>\n
Calcium homeostasis<\/strong><\/td>\nMaintained; anti-excitotoxic [2]<\/td>\nDysregulated vulnerability [6]<\/td>\nCell death in metabolically stressed neurons [4, 5]<\/td>\n<\/tr>\n
Antioxidant defense<\/strong><\/td>\nEnhanced; ROS buffering [2]<\/td>\nDiminished; oxidative stress [3, 4]<\/td>\nMitochondrial injury, glial activation [3]<\/td>\n<\/tr>\n
Cholesterol trafficking<\/strong><\/td>\nEfficient transport\/clearance [5]<\/td>\nImpaired; plaque-associated pathways [5]<\/td>\nLipid catabolism and myelin breakdown [4, 5]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The \u201chealthy cell bias of estrogen action\u201d model proposes that hormone therapy benefits depend on the biologic condition of the neural system at the time estrogen is introduced. [2, 4] In metabolically intact neurons, estrogen tends to support homeostasis and antioxidant capacity; however, when the system is already in a degenerative or hypometabolic state, estrogen can intensify injury by increasing energetic demand on dysregulated pathways. [2, 4] Timing therefore matters for a 57-year-old: initiation of therapy within roughly ten years of the final menstrual period (FMP) is more often associated with favorable cardiometabolic and cognitive risk patterns, while later initiation may provide less benefit. [6, 7, 8]<\/p>\n

Affective Regulation and the Window of Vulnerability to Stress<\/h3>\n

The menopause transition is widely described as a \u201cwindow of vulnerability\u201d for new or worsening depressive symptoms, anxiety, and irritability. [9, 10] For a 57-year-old woman reporting heightened anxiety and irritability after a major stressor two years earlier, a key mechanism is the intersection of estrogen withdrawal with serotonergic regulation and steroid-linked mood circuitry. [1, 11] Serotonin neurons in the midbrain raphe express estrogen receptor beta and progestin receptors, making them direct targets of ovarian steroids. [11] Estrogen supports serotonergic function in part by regulating synthesis-related pathways (including TPH2-linked mechanisms) and stress responsivity. [11] When estrogen levels fall\u2014or fluctuate sharply\u2014the serotonin system can become more stress-reactive, often presenting clinically as irritability and reduced coping capacity. [11]<\/p>\n

The \u201cEstradiol Withdrawal Hypothesis\u201d emphasizes that rapid physiologic shifts, not only low absolute hormone levels, can destabilize mood. [12, 13] Experimental crossover designs show that women with a history of perimenopausal depression (PMD) can experience clinically meaningful symptom recurrence when switched from estradiol to placebo, whereas women without such histories often remain stable under the same manipulation. [12] This pattern supports hormone-flux sensitivity in a biologically susceptible subgroup. [13, 14] For the patient in question, the major stress event two years prior\u2014potentially near the time of her FMP\u2014may have served as an amplifying trigger in a system already sensitized by fluctuating hormones. [13, 14]<\/p>\n

\"\"<\/p>\n

Table 2. Risk Factors for Affective Disorders During the Menopausal Transition<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Factor<\/strong><\/td>\nAssociation with Menopausal Depression\/Anxiety<\/strong><\/td>\nRisk Ratio \/ Odds Ratio (as reported)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
History of depression<\/strong><\/td>\nStrongest predictor of new\/recurrent episodes [9, 10]<\/td>\nOften ~OR 2\u20135 (varies by cohort) [9]<\/td>\n<\/tr>\n
Menopausal status<\/strong><\/td>\nPerimenopause vs premenopause increases risk [9, 10]<\/td>\nOften ~OR ~2 (varies by definition) [9]<\/td>\n<\/tr>\n
Hormone variability<\/strong><\/td>\nRapid fluctuations in E2\/FSH predict symptoms [13, 14]<\/td>\nPredictive association in longitudinal work [13, 14]<\/td>\n<\/tr>\n
Life stressors<\/strong><\/td>\nTrauma\/strain\/lack of support modulate risk [13, 14]<\/td>\nStrong interaction effects [13, 14]<\/td>\n<\/tr>\n
Vasomotor symptoms<\/strong><\/td>\nVMS burden linked to sleep\/mood decline [1, 15]<\/td>\nCorrelational + bidirectional models [15]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Furthermore, ovarian hormones modulate the hypothalamic-pituitary-adrenal (HPA) axis, which governs the stress response. [11] Estrogen typically facilitates a more regulated stress response; withdrawal can increase stress reactivity and alter cortisol feedback sensitivity. [11] Chronic stress combined with low estrogen may reduce physiologic buffering capacity, plausibly worsening irritability and anxiety in vulnerable patients. [11] For a woman at age 57 whose symptoms intensified after a major stressor at age 55, the clinical picture is consistent with an unregulated stress response compounded by postmenopausal neurochemical and metabolic shifts. [11]<\/p>\n

Estrogen Receptor Signaling and Neuroplasticity<\/h3>\n

Estrogens exert their effects through genomic and non-genomic signaling mediated by estrogen receptor pathways in brain regions critical for memory and emotional regulation (hippocampus, prefrontal cortex). [1, 2, 16] 17\u03b2-estradiol (E2) is the predominant and most potent estrogen during reproductive years, while estrone (E1) becomes relatively more prominent after menopause due to peripheral conversion. [1] Estradiol supports neuroplasticity via pathways linked to synaptic maintenance and neurotrophin signaling (including BDNF-associated effects). [2, 16]<\/p>\n

Evidence suggests that E2-based approaches may be more consistently aligned with cognitive and mood support than E1-heavy formulations. [6, 7] The density and sensitivity of estrogen signaling systems may shift during the transition, and subjective memory complaints and mood lability are common clinical correlates. [16, 17]<\/p>\n

Table 3. Estrogen Variants and Their Impact on Neural Health<\/strong><\/p>\n\n\n\n\n\n\n\n
Estrogen Type<\/strong><\/td>\nPrimary Biological Source<\/strong><\/td>\nEffect on Neuroplasticity<\/strong><\/td>\nClinical Notes<\/strong><\/td>\n<\/tr>\n<\/thead>\n
17\u03b2-Estradiol (E2)<\/strong><\/td>\nOvarian follicles; local brain [1, 2]<\/td>\nSupports synaptic function [2, 16]<\/td>\nUsed in many MHT; route matters [7]<\/td>\n<\/tr>\n
Estrone (E1)<\/strong><\/td>\nPeripheral adipose conversion [1]<\/td>\nLess consistent benefit vs E2 [6, 17]<\/td>\nDominant postmenopause fraction [1]<\/td>\n<\/tr>\n
Estetrol (E4)<\/strong><\/td>\nFetal liver\u2013derived [18]<\/td>\nSelective tissue profile; evolving [18, 19]<\/td>\nE4COMFORT design published [19]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Vasomotor Symptom Trajectories and Racial Disparities<\/strong><\/p>\n

Vasomotor symptoms (VMS), such as hot flashes and night sweats, arise from hypothalamic thermoregulatory zone narrowing in the context of estrogen withdrawal. [1, 15] Large cohort findings indicate that frequent VMS can persist for many years, with meaningful racial and ethnic disparities in symptom duration and post-FMP persistence. [20]<\/p>\n

\"\"<\/strong><\/p>\n

Table 4. Duration of Vasomotor Symptoms by Racial and Ethnic Group (Cohort Findings)<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Racial\/Ethnic Group<\/strong><\/td>\nMedian VMS Duration (years)<\/strong><\/td>\nMedian Post-FMP Persistence (years)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
African American<\/strong><\/td>\n10.1 [20]<\/td>\n6.0 [20]<\/td>\n<\/tr>\n
Hispanic<\/strong><\/td>\n8.9 [20]<\/td>\n6.4 [20]<\/td>\n<\/tr>\n
White (Non-Hispanic)<\/strong><\/td>\n6.5 [20]<\/td>\n4.6 [20]<\/td>\n<\/tr>\n
Chinese<\/strong><\/td>\n5.4 [20]<\/td>\n3.5 [20]<\/td>\n<\/tr>\n
Japanese<\/strong><\/td>\n4.8 [20]<\/td>\n3.3 [20]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cardiovascular Health and the Timing Hypothesis<\/h3>\n

Cardiovascular disease (CVD) incidence rises sharply after menopause. [1] Estrogen supports vascular function in part via nitric oxide\u2013mediated vasodilation and effects on endothelial function. [8] The \u201ctiming hypothesis\u201d suggests that menopausal hormone therapy initiated in women younger than 60 or within 10 years of menopause onset is less likely to increase CVD risk and may be associated with more favorable outcomes than later initiation. [7, 8]<\/p>\n

Initiating therapy later (eg, >10 years postmenopause or after age 65) is more consistently associated with thromboembolic and stroke risks, in part because established vascular pathology may be less responsive to estrogen\u2019s protective mechanisms. [7, 8] For a 57-year-old woman, initiating treatment generally remains within the favorable window when indicated and when risk screening is appropriate. [7, 8]<\/p>\n

\"\"<\/p>\n

Table 5. Cardiovascular and Cognitive Outcomes by HRT Initiation Timing<\/strong><\/p>\n\n\n\n\n\n\n\n
Timing Window<\/strong><\/td>\nCardiovascular Effect<\/strong><\/td>\nCognitive \/ AD Risk Effect<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Early postmenopause<\/strong> (<10 yrs)<\/td>\nMore favorable profile [7, 8]<\/td>\nPotentially more favorable framing [6, 17]<\/td>\n<\/tr>\n
Late postmenopause<\/strong> (>10 yrs)<\/td>\nHigher adverse event signals [7, 8]<\/td>\nLess consistent benefit; cautious [7, 17]<\/td>\n<\/tr>\n
Age >65 years<\/strong><\/td>\nHigher thromboembolic risk [7, 8]<\/td>\nDementia risk signals in late start [7]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Thromboembolic Risk and the Route of Administration<\/h3>\n

One of the most significant safety considerations in prescribing hormone therapy is venous thromboembolism (VTE). Oral estrogen undergoes hepatic first-pass metabolism, increasing prothrombotic factors and activating coagulation pathways. [21] Observational and clinical data show oral regimens are associated with increased VTE risk. [21, 22]<\/p>\n

In contrast, transdermal estrogen bypasses hepatic first-pass metabolism and is associated with lower or neutral VTE risk signals in comparative analyses. [22] For women with risk factors such as obesity or smoking history, transdermal estrogen is commonly preferred when hormone therapy is indicated. [7, 22]<\/p>\n

Table 6. VTE Risk by Regimen and Route (Comparative Evidence)<\/strong><\/p>\n\n\n\n\n\n\n\n
HT Regimen<\/strong><\/td>\nVTE Association<\/strong><\/td>\nEvidence Notes<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Oral estrogen (general)<\/strong><\/td>\nIncreased VTE risk [21, 22]<\/td>\nRisk varies by formulation and population [21, 22]<\/td>\n<\/tr>\n
Transdermal estrogen<\/strong><\/td>\nLower\/neutral risk vs oral [22]<\/td>\nPreferred in higher-risk profiles [7, 22]<\/td>\n<\/tr>\n
Progestogen effects<\/strong><\/td>\nProgestogen choice matters [23]<\/td>\nMicronized progesterone often favored [23]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/p>\n

Oncological Perspectives: Re-evaluating Breast Cancer Risk<\/h3>\n

The 2002 Women\u2019s Health Initiative (WHI) report significantly influenced clinical practice by identifying increased invasive breast cancer risk with combined estrogen (CEE) and medroxyprogesterone acetate (MPA). [24] Long-term follow-up added nuance: among women with hysterectomy randomized to estrogen alone, breast cancer incidence and mortality were lower than placebo in extended analyses. [25]<\/p>\n

Across studies, risk appears to be driven substantially by the progestogen component, particularly synthetic progestins. [23] Micronized progesterone is often preferred in contemporary practice discussions because comparative evidence suggests more favorable risk profiles relative to certain synthetic progestins, with potential sleep-related benefits. [7, 23]<\/p>\n

The Role of Androgens and Testosterone Therapy<\/h3>\n

Testosterone is a crucial hormone in female physiology, and androgen levels decline with age and menopause stage. [26] Physiologic-dose testosterone has evidence-based benefit for hypoactive sexual desire disorder (HSDD) and may improve sexual function without virilization when appropriately dosed and monitored. [26] Some clinical literature and expert discussion also report benefits in energy and well-being in selected patients, though indications beyond HSDD require careful risk-benefit framing. [26, 27]<\/p>\n

Table 7. Testosterone in Women: Common Myths vs Evidence<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Common Myth<\/strong><\/td>\nClinical Reality \/ Evidence<\/strong><\/td>\n<\/tr>\n<\/thead>\n
\u201cTestosterone is only for men\u201d<\/strong><\/td>\nConsensus recognizes therapy primarily for HSDD [26]<\/td>\n<\/tr>\n
\u201cIt causes masculinization\u201d<\/strong><\/td>\nLow-dose regimens minimize virilization risk [26]<\/td>\n<\/tr>\n
\u201cIt increases aggression\u201d<\/strong><\/td>\nNo routine aggression increase at physiologic doses [26]<\/td>\n<\/tr>\n
\u201cIt\u2019s only for libido\u201d<\/strong><\/td>\nPrimary supported indication is HSDD [26, 27]<\/td>\n<\/tr>\n
\u201cIt causes liver damage\u201d<\/strong><\/td>\nNon-oral approaches avoid first-pass issues [26]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Socioeconomic Position, Workforce, and Interpersonal Dynamics<\/h3>\n

The age at natural menopause reflects interactions among genetics, exposures, and socioeconomic position. [28] Higher educational attainment is associated with later menopause, while socioeconomic adversity is linked to earlier onset. [28] This transition occurs during peak professional years, where RAND estimates substantial annual productivity losses attributable to symptoms. [29] Furthermore, menopausal symptoms can affect interpersonal dynamics; divorce rates among adults over 50 have risen substantially since 1990, with women initiating a majority of these divorces. [30]<\/p>\n

\"\"<\/p>\n

Next-Generation Estrogen: Estetrol (E4)<\/h3>\n

Estetrol (E4) is a naturally occurring estrogen produced by the fetal liver and developed as a therapeutic candidate with selective tissue activity. [18] The E4COMFORT I and II trial design has been published in Maturitas<\/em> (January 2026), evaluating E4 15 mg and 20 mg for reduction in moderate-to-severe VMS, with long-term safety evaluation including endometrial safety. [19] ClinicalTrials registration includes NCT04209543 and NCT04090957. [19]<\/p>\n

Clinical Synthesis: Managing the 57-Year-Old Patient<\/h3>\n

For a 57-year-old postmenopausal woman experiencing increased irritability and anxiety following a significant stress event, the therapeutic goal is to restore neuroendocrine stability while minimizing risks. [7, 8] Her symptom pattern fits a plausible interaction between hormone variability, serotonergic stress vulnerability, and HPA-axis dysregulation. [13, 14, 11]<\/p>\n

Recommended Assessment and Treatment Hierarchy<\/h3>\n
    \n
  1. Determine stage and severity:<\/strong> Quantify irritability\/anxiety impact on quality of life and identify alignment with the “window of vulnerability.” [1, 9, 10]<\/li>\n
  2. Establish baseline risks:<\/strong> Evaluate cardiovascular markers, breast cancer risk, and VTE profile. [7, 21, 22]<\/li>\n
  3. Select optimized HT regimen:<\/strong> Prefer transdermal 17\u03b2-estradiol and micronized progesterone to minimize VTE and oncological risk signals. [7, 22, 23]<\/li>\n
  4. Integrative support:<\/strong> Address behavioral interventions that improve sleep and support stress resilience, given the coupling between sleep disruption and mood. [1, 15]<\/li>\n<\/ol>\n

    \"\"<\/p>\n

    \"\"<\/p>\n

    \"\"<\/p>\n

    References<\/h3>\n
      \n
    1. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management.\u00a0Endocrinol Metab Clin North Am<\/i>. 2015;44(3):497-515. doi:10.1016\/j.ecl.2015.05.001<\/li>\n
    2. Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body.\u00a0Front Neuroendocrinol<\/i>. 2014;35(1):8-30. doi:10.1016\/j.yfrne.2013.08.001<\/li>\n
    3. Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.\u00a0Neurology<\/i>. 2017;89(13):1382-1390. doi:10.1212\/WNL.0000000000004425<\/li>\n
    4. Yao J, Brinton RD. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer’s disease.\u00a0Adv Pharmacol<\/i>. 2012;64:327-371. doi:10.1016\/B978-0-12-394816-8.00010-6<\/li>\n
    5. Adlimoghaddam A, Fontaine KM, Albensi BC. Age- and sex-associated alterations in hypothalamic mitochondrial bioenergetics and inflammatory-associated signaling in the 3xTg mouse model of Alzheimer’s disease.\u00a0Biol Sex Differ<\/i>. 2024;15(1):95. Published 2024 Nov 25. doi:10.1186\/s13293-024-00671-7<\/li>\n
    6. Sochocka M, Karska J, Pszczo\u0142owska M, et al. Cognitive Decline in Early and Premature Menopause.\u00a0Int J Mol Sci<\/i>. 2023;24(7):6566. Published 2023 Mar 31. doi:10.3390\/ijms24076566<\/li>\n
    7. \u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society.\u00a0Menopause<\/i>. 2022;29(7):767-794. doi:10.1097\/GME.0000000000002028<\/li>\n
    8. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.\u00a0Circulation<\/i>. 2020;142(25):e506-e532. doi:10.1161\/CIR.0000000000000912<\/li>\n
    9. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations.\u00a0J Womens Health (Larchmt)<\/i>. 2019;28(2):117-134. doi:10.1089\/jwh.2018.27099.mensocrec<\/li>\n
    10. Kulkarni J, Gurvich C, Mu E, et al. Menopause depression: Under recognised and poorly treated.\u00a0Aust N Z J Psychiatry<\/i>. 2024;58(8):636-640. doi:10.1177\/00048674241253944<\/li>\n
    11. Rubinow DR, Schmidt PJ. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome.\u00a0Front Neuroendocrinol<\/i>. 2006;27(2):210-216. doi:10.1016\/j.yfrne.2006.02.003<\/li>\n
    12. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.\u00a0JAMA Psychiatry<\/i>. 2015;72(7):714-726. doi:10.1001\/jamapsychiatry.2015.0111<\/li>\n
    13. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition.\u00a0Menopause<\/i>. 2016;23(3):257-266. doi:10.1097\/GME.0000000000000528<\/li>\n
    14. Miller VM, Kling JM, Files JA, et al. What’s in a name: are menopausal “hot flashes” a symptom of menopause or a manifestation of neurovascular dysregulation?.\u00a0Menopause<\/i>. 2018;25(6):700-703. doi:10.1097\/GME.0000000000001065<\/li>\n
    15. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women’s Health across the Nation.\u00a0Obstet Gynecol Clin North Am<\/i>. 2011;38(3):489-501. doi:10.1016\/j.ogc.2011.05.006<\/li>\n
    16. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition.\u00a0Obstet Gynecol Clin North Am<\/i>. 2011;38(3):519-535. doi:10.1016\/j.ogc.2011.05.007<\/li>\n
    17. Russell JK, Jones CK, Newhouse PA. The Role of Estrogen in Brain and Cognitive Aging.\u00a0Neurotherapeutics<\/i>. 2019;16(3):649-665. doi:10.1007\/s13311-019-00766-9<\/li>\n
    18. Coelingh Bennink HJT, Gosden R, Stanczyk FZ, Adashi EY. The rediscovery of estetrol and its implications for estrogen treatment.\u00a0Menopause<\/i>. 2025;32(7):648-651. Published 2025 Jul 1. doi:10.1097\/GME.0000000000002537<\/li>\n
    19. Panay N, Simoncini T, Taziaux M, et al. Estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women: The design of the E4COMFORT I and II trials.\u00a0Maturitas<\/i>. 2026;204:108781. doi:10.1016\/j.maturitas.2025.108781<\/li>\n
    20. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition.\u00a0JAMA Intern Med<\/i>. 2015;175(4):531-539. doi:10.1001\/jamainternmed.2014.8063<\/li>\n
    21. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.\u00a0BMJ<\/i>. 2008;336(7655):1227-1231. doi:10.1136\/bmj.39555.441944.BE<\/li>\n
    22. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.\u00a0BMJ<\/i>. 2019;364:k4810. Published 2019 Jan 9. doi:10.1136\/bmj.k4810<\/li>\n
    23. Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.\u00a0Climacteric<\/i>. 2018;21(4):341-345. doi:10.1080\/13697137.2018.1446931<\/li>\n
    24. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.\u00a0JAMA<\/i>. 2002;288(3):321-333. doi:10.1001\/jama.288.3.321<\/li>\n
    25. Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials.\u00a0JAMA Oncol<\/i>. 2015;1(3):296-305. doi:10.1001\/jamaoncol.2015.0494<\/li>\n
    26. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women.\u00a0J Clin Endocrinol Metab<\/i>. 2019;104(10):4660-4666. doi:10.1210\/jc.2019-01603<\/li>\n
    27. Glaser R, Dimitrakakis C. Testosterone therapy in women: myths and misconceptions.\u00a0Maturitas<\/i>. 2013;74(3):230-234. doi:10.1016\/j.maturitas.2013.01.003<\/li>\n
    28. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents.\u00a0Int J Epidemiol<\/i>. 2014;43(5):1542-1562. doi:10.1093\/ije\/dyu094<\/li>\n
    29. RAND Corporation.\u00a0The Economic Impacts of Menopause in the United States<\/i>. 2022. https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/research_reports\/RRA4200\/RRA4292-1\/RAND_RRA4292-1.pdf<\/a><\/li>\n
    30. Brown SL, Lin IF. The gray divorce revolution: rising divorce among middle-aged and older adults, 1990-2010.\u00a0J Gerontol B Psychol Sci Soc Sci<\/i>. 2012;67(6):731-741. doi:10.1093\/geronb\/gbs089<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Die Menopause ist nicht einfach nur das lokale Herunterfahren der Fortpflanzungsfunktion; sie ist eine weitreichende neuroendokrine Neukonfiguration, die durch sinkende Spiegel und unvorhersehbare Schwankungen der Ovarialsteroide gekennzeichnet ist. F\u00fcr das weibliche Gehirn funktioniert diese Umstellung wie ein metabolischer \u201cReset\u201d.\u201d <\/p>","protected":false},"author":16,"featured_media":9287,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[231,223,225,226],"tags":[],"class_list":["post-9171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inflammation","category-plaque-arteries-and-disease","category-risk-genetics-special-populations","category-special-populations"],"acf":[],"yoast_head":"\nMenopause Endocrine Cardiovascular Risks - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/de\/menopause-endokrine-kardiovaskulare-risiken\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menopause Endocrine Cardiovascular Risks - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"The menopausal transition is not simply a local shutdown of reproductive function; it is a far-reaching neuroendocrine reconfiguration marked by declining levels and unpredictable oscillations of ovarian steroids. For the female brain, this shift functions like a metabolic \u201creset.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/de\/menopause-endokrine-kardiovaskulare-risiken\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-08T16:08:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T14:55:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"15\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Menopause Endocrine Cardiovascular Risks\",\"datePublished\":\"2026-02-08T16:08:40+00:00\",\"dateModified\":\"2026-07-16T14:55:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/\"},\"wordCount\":2714,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-29b.jpg\",\"articleSection\":[\"Inflammation\",\"Plaque, Arteries and Disease\",\"Risk, Genetics and Special Populations\",\"Special Populations\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/\",\"name\":\"Menopause Endocrine Cardiovascular Risks - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-29b.jpg\",\"datePublished\":\"2026-02-08T16:08:40+00:00\",\"dateModified\":\"2026-07-16T14:55:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-29b.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-29b.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/menopause-endocrine-cardiovascular-risks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menopause Endocrine Cardiovascular Risks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menopause Endokrine Kardiovaskul\u00e4re Risiken - Die f\u00fchrende Plattform f\u00fcr Herzgesundheitsaufkl\u00e4rung","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/de\/menopause-endokrine-kardiovaskulare-risiken\/","og_locale":"de_DE","og_type":"article","og_title":"Menopause Endocrine Cardiovascular Risks - The Premiere Heart Health Education Platform","og_description":"The menopausal transition is not simply a local shutdown of reproductive function; it is a far-reaching neuroendocrine reconfiguration marked by declining levels and unpredictable oscillations of ovarian steroids. For the female brain, this shift functions like a metabolic \u201creset.\u201d","og_url":"https:\/\/www.curingheartdisease.com\/de\/menopause-endokrine-kardiovaskulare-risiken\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-02-08T16:08:40+00:00","article_modified_time":"2026-07-16T14:55:43+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"Verfasst von":"Peter Megdal PhD","Gesch\u00e4tzte Lesezeit":"15\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Menopause Endocrine Cardiovascular Risks","datePublished":"2026-02-08T16:08:40+00:00","dateModified":"2026-07-16T14:55:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/"},"wordCount":2714,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg","articleSection":["Inflammation","Plaque, Arteries and Disease","Risk, Genetics and Special Populations","Special Populations"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/","url":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/","name":"Menopause Endokrine Kardiovaskul\u00e4re Risiken - Die f\u00fchrende Plattform f\u00fcr Herzgesundheitsaufkl\u00e4rung","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg","datePublished":"2026-02-08T16:08:40+00:00","dateModified":"2026-07-16T14:55:43+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-29b.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/menopause-endocrine-cardiovascular-risks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Menopause Endocrine Cardiovascular Risks"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"Die f\u00fchrende Bildungsplattform f\u00fcr Herzgesundheit","description":"Der \u00d6ffentlichkeit Informationen nach dem neuesten Stand der Wissenschaft dar\u00fcber zug\u00e4nglich zu machen, wie Herzkrankheiten r\u00fcckg\u00e4ngig gemacht werden k\u00f6nnen. Dies ist eine evidenzbasierte Organisation, die die besten verf\u00fcgbaren wissenschaftlichen Erkenntnisse nutzt, einschlie\u00dflich Ern\u00e4hrung, Bewegung, Medikamente und anderer Ressourcen, um diese Krankheit optimal zu bek\u00e4mpfen.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC ist eine unabh\u00e4ngige Organisation f\u00fcr kardiovaskul\u00e4re Gesundheitsaufkl\u00e4rung, die evidenzbasierte Artikel, Videos, Podcasts und Lehrmittel zu den Themen Vorbeugung von Herz-Kreislauf-Erkrankungen, Lipidwissenschaft, Ern\u00e4hrung, Bewegung und verwandten Gesundheitsthemen ver\u00f6ffentlicht.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD ist Ern\u00e4hrungsforscher, Aufkl\u00e4rer im Bereich Herz-Kreislauf-Gesundheit, publizierender Wissenschaftler und langj\u00e4hriger Leistungsradfahrer. Er promovierte in Ern\u00e4hrungswissenschaften an der University of Massachusetts und ver\u00f6ffentlicht \u00fcber \u201eCuring Heart Disease\u201c evidenzbasierte Informationen zur Herz-Kreislauf-Gesundheit.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/posts\/9171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/comments?post=9171"}],"version-history":[{"count":20,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/posts\/9171\/revisions"}],"predecessor-version":[{"id":12107,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/posts\/9171\/revisions\/12107"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/media\/9287"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/media?parent=9171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/categories?post=9171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/de\/wp-json\/wp\/v2\/tags?post=9171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}